SEC Filing Summary

Robert E. Hoffman, Chief Executive Officer of CytoDyn Inc., was granted 2,500,000 non-qualified stock options on October 20, 2026. These options, exercisable under the Issuer's 2012 Equity Incentive Plan, have an exercise price of $0.25 per share and expire on October 16, 2036. The options vest in stages, with 625,000 shares vesting on October 16, 2027, and the remainder vesting monthly from November 16, 2027, to October 16, 2030. This transaction is reported on Form 4.